Salute e Benessere
Combined General Meeting of November 27, 2025 - Availability of the preparatory documents
– Inventiva (Euronext Paris and Nasdaq : IVA) (“ ” or the “ ”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the availability of the preparatory documents for the Combined General Meeting of November 27, 2025.
Shareholders are invited to participate in the Combined General Meeting that will be held on November 27 at
9 a.m. CEST at Hôtel Villa M, 24 – 30 Boulevard Pasteur, 75015 Paris (France).
The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on how to attend and vote at the Combined General Meeting, was published in the (BALO) n°126 of October 20, 2025 and a translation was filed with the Securities and Exchange Commission on October 20, 2025.
This meeting is convened in particular to approve, following the appointment of a new Chief Executive Officer announced on October 1, 2025, (i) the terms of the compensation policy applicable to the new Chief Executive Officer, Mr. Andrew Obenshain , (ii) the terms of the agreement setting out the conditions of departure of the former Chief Executive Officer, Mr. Frédéric Cren, and to authorize the Board of Directors to partially waive the presence and performance conditions attached to certain free share plans granted to Mr. Cren, beyond the provisions of the compensation policy applicable to Mr. Cren, in recognition of his significant contributions to the Company . Mr. Frédéric Cren's term of office ended on September 30, 2025. He is working with Mr. Obenshain to ensure a smooth transition and continuity of the Company's strategic priorities.
Information and documents pertaining to the Combined General Meeting are available on the Company's website (www.inventivapharma.com, section "Investors" / "Shareholder Meetings").
In accordance with articles R. 225-83 and R. 225-89 of the French Commercial Code, documents that must be available for the shareholders for the purpose of general meetings will be available at the Company's registered office, 50, Rue de Dijon, 21121 Daix (France), the fifteenth day prior to the Combined General Meeting.
Documents listed in Article R.22-10-23 of the French Commercial Code are available on Inventiva’s website mentioned above as of tomorrow, the twenty-first day that precedes the General Meeting.
In accordance with applicable regulatory provisions:
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.
Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). https://inventivapharma.com/
Contacts
The compensation policy for Mr. Andrew Obenshain, as determined by the Board of Directors based on the work of the Appointments and Compensation Committee, is available on the Company's website under the heading “Shareholders' Meetings.”
The main terms of the agreement entered into with Mr. Frédéric Cren, as approved by the Board of Directors based on the work of the Appointments and Compensation Committee, are available on the Company's website under the “Governance” section, under the “Regulated Agreements” tab. The resolution submitted to the General Meeting and the relevant paragraphs of the report of the Board of Directors are available on the Company's website under the heading “General Meetings.”
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti